ArticleJournal of Parkinson's disease2016
Nilotinib - Differentiating the Hope from the Hype.
Article in Journal of Parkinson's disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- What medicines do people with Parkinson's disease want?Journal of Parkinson's disease · 2026Review
- Yoga for Neurodegenerative Disorders: Therapeutic Effects, Mechanisms, and Applications in Alzheimer's and Parkinson's Disease.Sports (Basel, Switzerland) · 2025Review
- Parkinson's disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment.Annals of medicine and surgery (2012) · 2023Review
- Therapeutics in the Pipeline TargetingPharmacological reviews · 2022Review
- Promising drug targets and associated therapeutic interventions in Parkinson's disease.Neural regeneration research · 2021Review
- A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.European journal of medicinal chemistry · 2020Review
- Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.Clinics in geriatric medicine · 2020Review
- Parkinson's Disease: We Care!Journal of Parkinson's disease · 2020Article
- Review
- Article
- Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.CNS drugs · 2019Review
- Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia.Case reports in neurological medicine · 2019Article
- New Frontiers in Parkinson's Disease: From Genetics to the Clinic.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Review
- Drug Repurposing in Parkinson's Disease.CNS drugs · 2018Review
- Article
- Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.Movement disorders : official journal of the Movement Disorder Society · 2018Review
- Emerging Treatment Approaches for Parkinson's Disease.Frontiers in neuroscience · 2018Review
- Therapeutic approaches to target alpha-synuclein pathology.Experimental neurology · 2017Review
- Alpha-synuclein and iron: two keys unlocking Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2017Review
- The c-Abl inhibitor in Parkinson disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We discuss a report in the current issue on clinical and biochemical findings from a safety trial using the cAbl tyrosine kinase inhibitor Nilotinib (150 mg or 300 mg given daily for 24 weeks) in a small group of patients with either advanced Parkinson's disease or Dementia with Lewy Bodies. Despite some side effects (one serious), the authors claim that Nilotinib, which is normally used at much higher doses for treating leukemia, is safe and tolerated. Furthermore, they report a possible benefit on motor and cognitive outcomes. We debate the safety of Nilotinib and the reported efficacy signals. We emphasize that due to the small sample size, and lack of a control group, it is impossible to rule out a placebo effect. We briefly discuss a range of aspects surrounding the current and possible future use of this cAbl inhibitor in patients with alpha-synucleinopathy, and what must now be done to obtain definitive information about its safety and efficacy in this population of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.